CHLORZOXAZONE | A207483 | ANDA REPOSITORY LLC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Pharmobedient Consulting, LLC FDA-2025-P-0344 · 8 docket documents Pharmobedient Consulting, LLC filed a suitability petition pursuant to section 505(j)(2)(C) of the FDC Act and 21 C.F.R. § 314.93 requesting that the FDA declare Chlorzoxazone Tablets, 125 mg suitable for submission in an ANDA, which differs in strength from the reference listed drug Paraflex (Chlor | Suitability | 2025-01-29 | Denied | Pharmobedient Consulting, LLC |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$2.55
per ea
Lowest NADAC/Unit
$2.55
per ea
Brand NDCs
0
Generic NDCs
1
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 69499033060CHLORZOXAZONE 250 MG TABLET | $2.55 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.